113209-68-0

Usage

Uses

Used in Pharmaceutical Research and Drug Discovery:
7-Fluoro-4-chromanone is used as a compound of interest for its potential applications in pharmaceutical research and drug discovery. Its unique structural properties and pharmacological activities make it a promising candidate for the development of novel drugs.
Used in Anti-inflammatory Applications:
7-Fluoro-4-chromanone is used as an anti-inflammatory agent due to its potential to modulate inflammatory pathways and reduce inflammation in various diseases and conditions.
Used in Antioxidant Applications:
7-Fluoro-4-chromanone is used as an antioxidant, helping to neutralize free radicals and protect cells from oxidative damage, which can contribute to the prevention and treatment of various diseases.
Used in Neuroprotective Applications:
7-Fluoro-4-chromanone is used for its potential neuroprotective effects, which may help in the treatment of neurodegenerative diseases by protecting neurons from damage and promoting neuronal survival.
Used in the Development of Novel Drugs:
7-Fluoro-4-chromanone is utilized in the development of novel drugs for the treatment of various diseases and conditions, leveraging its potential pharmacological activities and structural properties to create new therapeutic agents.

InChI:InChI=1/C9H7FO2/c10-6-1-2-7-8(11)3-4-12-9(7)5-6/h1-2,5H,3-4H2

Upstream product

• 590-92-1 3-Bromopropionic acid 
• 372-20-3 3-fluorophenol 
• 10026-13-8 phosphorus pentachloride 
• 87411-27-6 3-(3-fluorophenoxy)propanecarboxylic acid 
• 133077-42-6 3-(3-fluorophenoxy)propanoic acid 
• 844648-05-1 3-(3-fluorophenoxy)propanenitrile 
• 1579-78-8 3-(4-fluoro-phenoxy)propionic acid 
• 104413-57-2 3-(4-fluorophenoxy)-1-propanol 
• 371-41-5 4-Fluorophenol 

Downstream Products

• 774163-31-4 7-fluorochroman-4-amine 
• 1610343-24-2 1-(1',4-dimethyl-1-phenyl-1H,1'H-[3,4'-bipyrazol]-5-yl)-3-(7-fluorochroman-4-yl)urea 
• 1202887-91-9 6-cyano-7-(4-(2',3'-dimethylbiphenyl-3-ylcarbamoyl)phenoxy)chroman-4-carboxylic acid 
• 1269508-49-7 methyl 6-cyano-7-(4-(2',3'-dimethylbiphenyl-3-ylcarbamoyl)phenoxy)chroman-4-carboxylate 
• 1202890-41-2 methyl 6-cyano-7-(4-(4'-methylbiphenyl-3-ylcarbamoyl)phenoxy)chroman-4-carboxylate 
• 1202887-89-5 6-cyano-7-(4-(4'-methylbiphenyl-3-ylcarbamoyl)phenoxy)chroman-4-carboxylic acid 
• 1202887-32-8 7-(4-((2-(4-chlorophenyl)cyclopropyl)carbamoyl)phenoxy)-6-cyano-3,4-dihydro-2H-chromene-4-carboxylic acid 
• 1202890-21-8 methyl 7-(4-((2-(4-chlorophenyl)cyclopropyl)carbamoyl)phenoxy)-6-cyano-3,4-dihydro-2H-chromene-4-carboxylate 
• 1202890-26-3 methyl 7-(4-(biphenyl-3-ylcarbamoyl)phenoxy)-6-cyanochroman-4-carboxylate 
• 1202889-79-9 methyl 7-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-6-cyano-4-methylchroman-4-carboxylate 
• 1202886-83-6 6-cyano-7-(4-(4-chlorophenethylcarbamoyl)phenoxy)chroman-4-carboxylic acid 
• 1202887-48-6 7-(4-(biphenyl-3-ylcarbamoyl)phenoxy)-6-cyanochroman-4-carboxylic acid 
• 1202886-89-2 7-(4-(4-chlorobenzyloxycarbamoyl)phenoxy)-6-cyanochroman-4-carboxylic acid 
• 1202889-77-7 methyl 7-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-6-cyanochroman-4-carboxylate 

Relevant academic research and scientific papers

Exploiting the Chromone Scaffold for the Development of Inhibitors of Corticosteroid Biosynthesis

The inhibition of corticosteroid biosynthesis could be considered as an emerging strategy to reduce their abnormally high levels, and in this framework CYP11B1 and CYP11B2 represent the most promising targets. In continuing our studies on flavonoid-like scaffolds as privileged structures in medicinal chemistry, in this paper we describe a small library of pyridyl- and imidazolylmethylchromones as potential inhibitors of these enzymes. Testing results proved that position 3 of the chromone scaffold is the most favorable for the introduction of the heme-coordinating heterocycles and, among them, the 4-imidazolyl moiety is the most convenient for the interaction with the heme iron of the selected cytochromes. A low nanomolar inhibitor of CYP11B1 (5c) was obtained, endowed with reasonable selectivity toward CYP11B2 and able to better discriminate with respect to CYP17 and CYP19.

Design, synthesis and biological evaluation of pyridyl substituted benzoxazepinones as potent and selective inhibitors of aldosterone synthase

Exorbitant aldosterone is closely associated with various severe diseases, including congestive heart failure and chronic kidney disease. As aldosterone synthase is the pivotal enzyme in aldosterone biosynthesis, its inhibition constitutes a promising tre

Steroid synthase inhibitors and therapeutic application thereof

The invention discloses a steroid synthase inhibitor and treatment application thereof, and belongs to the field of medicines. The compound capable of being used as the medicine has the effect of inhibiting steroid synthase, is high in inhibition rate and

Rapid synthesis of 4-arylchromenes from ortho-substituted alkynols: A versatile access to restricted iso combretastatin A-4 analogues as antitumor agents

Potent anticancer 4-arylchromene agents 6, as restricted isoCA-4 analogues, were prepared with excellent yields by a rapid and versatile synthetic pathway. First, in the presence of PTSA in EtOH, a variety of arylalkynols 9 were transformed into substitut

Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application

The design and synthesis of novel HIV-1 protease inhibitors (PIs) (1-22), which display high potency against HIV-1 wild-type and multi-PI-resistant HIV-mutant clinical isolates, is described. Lead optimization was initiated from compound 1, a Phe-Phe hydroxyethylene peptidomimetic PI, and was directed towards the discovery of new PIs suitable for a long-acting (LA) injectable drug application. Introducing a heterocyclic 6-methoxy-3-pyridinyl or a 6-(dimethylamino)-3-pyridinyl moiety (R3) at the para-position of the P1′ benzyl fragment generated compounds with antiviral potency in the low single digit nanomolar range. Halogenation or alkylation of the metabolic hot spots on the various aromatic rings resulted in PIs with high stability against degradation in human liver microsomes and low plasma clearance in rats. Replacing the chromanolamine moiety (R1) in the P2 protease binding site by a cyclopentanolamine or a cyclohexanolamine derivative provided a series of high clearance PIs (16-22) with EC50s on wild-type HIV-1 in the range of 0.8-1.8 nM. PIs 18 and 22, formulated as nanosuspensions, showed gradual but sustained and complete release from the injection site over two months in rats, and were therefore identified as interesting candidates for a LA injectable drug application for treating HIV/AIDS.

SPIROAMINODIHYDROTHIAZINE DERIVATIVES

A compound represented by the general formula (I): or a pharmaceutically acceptable salt thereof, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer- type dementia.

PHARMACEUTICALLY ACTIVE 6-N-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES

The invention provides compounds of the formula (0), in which the substituents and symbols are as defined in the description. The compounds inhibit the secretion of gastric acid.

CHROMAN DERIVATIVES AND THEIR USE AS 5-HT RECEPTOR LIGANDS

Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, R1, R2, R3 and R4 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula (I).

CHROMAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CNS DISORDERS

Compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, R1, R2, R3 and R4 are as defined herein. Also provided are methods for preparing, compositions comprising, and met

Quinoxaline compounds

Certain amidophenyl-sulfonylamino-quinoxaline compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.